Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04756895
Other study ID # 2021-600
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2021
Est. completion date August 6, 2021

Study information

Verified date September 2021
Source CR-CSSS Champlain-Charles-Le Moyne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot study is a prospective, randomized, controlled, open-label trial to assess the feasibility of a randomized controlled trial of sufficient quality that would assess the efficacy and safety of vancomycin adjustments according to Area under the curve/Minimal inhibitory concentration (AUC0-24h/MIC) calculated by the Bayesian approach rather than by a trough dosage. Randomization will be stratified according to infection severity. Approximately 60 subjects meeting all inclusion and no exclusion criteria will be randomized to have pharmacists perform vancomycin dose adjustments with AUC0-24h / MIC calculated by the Bayesian approach versus the trough dosage approach.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date August 6, 2021
Est. primary completion date August 6, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At least 18 years of age; - Hospitalized patients - Suspected or confirmed infection; - Anticipated IV vancomycin treatment for 24 hours or more. Exclusion Criteria: - Patients with renal replacement therapy (peritoneal dialysis, continuous renal replacement therapy or hemodialysis); - Treatment of vancomycin in continuous infusion;

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Vancomycin dose adjustment using the Bayesian method
This intervention is the experimental method. The AUC/MIC target is 400-600 mg*hour/L.
Vancomycin dose adjustment using the trough level method
This intervention is the standard method. Previous clinical guidelines recommended this method. The trough target is 10-15 mg/L for non-severe infections and 15-20 mg/L for severe infections.

Locations

Country Name City State
Canada Charles-Le Moyne Hospital Greenfield Park Quebec

Sponsors (1)

Lead Sponsor Collaborator
CR-CSSS Champlain-Charles-Le Moyne

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validation of The Research Protocol Evaluation of adhesion rate to the sampling protocol of 80% or more and adhesion rate to software recommendations of 90% or more Through study completion, an average of 2 weeks
Primary Evaluation of Recruitment Evaluation of consent rate of 30% or more and the number of patients recruited per month of 10 or more Baseline
Secondary The proportion of patients who reach a therapeutic level in the first 48 hours Percentage of patients who reach a therapeutic level in the first 48 hours At 48 hours after the first dose of vancomycin
Secondary Time to reach the vancomycin target Number of hours necessary to reach the vancomycin target. Number of hours will be classified in the following categories: 24-48 hours, 49-96 hours, 97 hours and above. During the vancomycin treatment
Secondary The number of adjustments required to reach the vancomycin target Number of dose adjustments required to reach the vancomycin target During the vancomycin treatment
Secondary The number of vancomycin dosage level monitoring to reach the vancomycin target The number of vancomycin dosage level monitoring to reach the vancomycin target During the vancomycin treatment
Secondary The proportion of vancomycin dosage level monitoring in the vancomycin target Percentage of vancomycin dosage level monitoring in the vancomycin target During the vancomycin treatment
Secondary The difference between the AUC calculated by the Bayesian method and the trapezoid method Difference in percentage of the vancomycin AUC calculated by the Bayesian method and the trapezoid method During the vancomycin treatment
Secondary The difference between the initial prescribed dose and the dose suggested by the Bayesian software. Difference in percentage of the initial prescribed dose and the dose suggested by the Bayesian software. Baseline
Secondary Proportion of acute kidney injury Percentage of acute kidney injury. During the vancomycin treatment
Secondary Average daily dose of vancomycin Average of the daily dose of vancomycin calculated in mg per kg of total body weight Through study completion, an average of 2 weeks
Secondary Operational Impact Evaluation of the impact on pharmacist's time required for monitoring vancomycin Immediately after the intervention
See also
  Status Clinical Trial Phase
Recruiting NCT06320626 - Pharmacokinetic-guided Dosing of Emicizumab Phase 4
Recruiting NCT05841667 - Impact of CES1 Genotype on Remimazolam
Completed NCT06355817 - Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration N/A
Not yet recruiting NCT01209481 - Impact of Educational Group Intervention on the Consumption of Fruit and Vegetables N/A
Terminated NCT01570465 - Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
Completed NCT04169646 - Prevention and Intervention of Neck Pain in Swiss Office-Workers N/A
Not yet recruiting NCT01943565 - Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study Phase 4
Completed NCT00519298 - Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects Phase 1
Completed NCT03541837 - Erector Spinae Plane Block and Pain Management in Cardiac Surgery N/A
Active, not recruiting NCT00809575 - Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
Completed NCT06383117 - Understanding Effects of Calcium on the Gut-Bone Axis N/A
Completed NCT05012046 - Effect of 100% Orange Juice on Food Intake and Glycemic Response in Adults N/A
Completed NCT05597969 - The Effect of an Application-based Health Intervention (FoodCoach) on Food Purchases in Switzerland N/A
Terminated NCT01817153 - Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock. Phase 2/Phase 3
Not yet recruiting NCT05123352 - Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies
Not yet recruiting NCT03728114 - Effects of RIC on Cognitive Function and Blood Oxygen Levels in Unacclimatized Adult at High Altitude N/A
Completed NCT01162863 - Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation N/A
Completed NCT05570435 - Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response N/A
Recruiting NCT03713931 - PUMA Implementation 2
Completed NCT04443231 - Prospective Clinical Study of Retinal Microvascular Alteration After ICL Implantation